The pleiotropic action of the drug was further confirmed by (i) the ability of the drug to reverse the cancer-driven dysbiosis of the oral microbiome, as measured by 16S RNA sequencing, and (ii) immunofluorescence of the tumor tissues before and after the drug administration showing immune system activation by recruitment of CD8+ Tc cells to the tumor as expected when TME experiences M2 to M1 reprogramming of TAM. The gene discussed is CD8A; the disease is cancer.